Medication info
Melfomin Extended-Release Tablet 500mg (Metformin Hydrochloride)

Melfomin Extended-Release Tablet 500mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
White, double-convex, rectangular extended-release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201601639 · Approved 2016.03.28 · Insurance code 648603250

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider 1000mg twice daily; both doses should be taken with meals. - In patients already receiving metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking 2000mg or more per day of immediate-release metformin. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to this medicine and determine the minimum effective dose. Blood hemoglobin A1c levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood hemoglobin A1c levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used to treat adult patients with Type 2 diabetes whose blood sugar control is insufficient with diet and exercise alone. It is particularly effective in overweight diabetic patients and can be used alone or in combination with other oral hypoglycemic agents or insulin. It helps improve blood sugar levels to aid in diabetes management.

How to take

Adult dose

The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider 1000mg twice daily; both doses should be taken with meals. - In patients already receiving metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking 2000mg or more per day of immediate-release metformin. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to this medicine and determine the minimum effective dose. Blood hemoglobin A1c levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood hemoglobin A1c levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Precautions

This medication can rarely cause a serious condition called lactic acidosis, so it is important to be aware of this symptom. Lactic acidosis may accompany symptoms such as muscle pain, difficulty breathing, weakness, and abdominal pain; if these symptoms appear, you should inform your doctor immediately. Additionally, caution is required when used with insulin or sulfonylureas as there is a risk of hypoglycemia. This medication should not be administered to patients with moderate to severe renal impairment, dehydration, severe infections, heart failure, or acute myocardial infarction. The administration of this medication should be paused before and after exams that use iodine contrast agents and should be restarted only after renal function has been confirmed to be normal. Patients with a history of allergic reactions to any of the ingredients in this medication should not use it. Since it can cross the placenta, it should not be used in cases of specific risks during pregnancy; however, it may be used at the discretion of a doctor if blood sugar control is needed during pregnancy. Nursing mothers should consult their doctor on whether to continue breastfeeding or to discontinue the drug, as this medication is secreted in breast milk. Elderly patients or those with compromised renal function may require dosage adjustments, and regular kidney function tests should be conducted. Side effects such as gastrointestinal disturbances, vitamin B12 deficiency, and skin rashes may occur, so any unusual symptoms should be reported. This medication may interact with other drugs, so it is crucial to inform healthcare professionals about any medications being taken. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking alcohol while on this medication. In situations such as surgery, severe trauma, or serious infections, this medication should be temporarily discontinued, and resumed after improvement. This medication should be swallowed whole without crushing or chewing, and it is normal for the tablet's coating to be expelled in the stool. Blood sugar control and kidney function should be monitored regularly while on this medication, and dosage adjustments or the continuation of treatment should be discussed with a doctor.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature. Proper storage will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

White, double-convex, rectangular extended-release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.